Travere Therapeutics

Investor Fact Sheet

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow.

Ticker	TVTX
Market Cap (B)[1]	$2.5
Shares Outst (M)[2]	90.9
Cash (M)[3]	$323

[1] As of 2/18/26. [2] As of 12/31/25. [3] Cash, cash equivalents and marketable securities as of December 31, 2025.

Strategic Priorities to Drive Significant Growth Now and in the Future

Solidify FILSPARI's **foundational position** in a growing IgAN market

Obtain approval and successfully launch FILSPARI **in FSGS** (4/13/26 PDUFA date)

Position **pegtibatinase** as the first potential disease-modifying therapy in HCU

FILSPARI Positioned as a First-in-Class Foundational Treatment in IgAN

One pill, once daily administration

Streamlined liver monitoring

Superior two-year proteinuria reduction vs active comparator irbesartan

FILSPARI®

stronger foundation for kidney preservation

Two-year safety data comparable to maximum-labeled dose irbesartan

Only therapy to date to demonstrate statistically significant slowing of kidney function decline in a Phase 3 study vs active comparator irbesartan

Flexibility for combination use and newly diagnosed patients with IgAN

U.S. Launch of FILSPARI Continues to Outperform Recent Benchmark Launches

FILSPARI: U.S. Net Product Sales (in $ millions)



TRAVERE THERAPEUTICS®

April 13, 2026 PDUFA Date: Obtain Approval and Successfully Launch FILSPARI in FSGS

1. **PARASOL**: a multi-stakeholder group of rare kidney disease experts recognized the variability and trial infeasibility of eGFR and aligned around proteinuria as a potential clinical trial endpoint.
2. **New analyses from DUPLEX**: validate PARASOL's conclusions and reinforce FILSPARI's potential as a nephroprotective therapy that may help delay progression to kidney failure.
3. **Significant unmet need with high urgency to treat**: potential for FILSPARI to become the only FDA-approved medicine indicated for patients with FSGS

FILSPARI Demonstrated Significantly Greater Proteinuria Reduction vs Active Comparator Across Pre-Specified Measurement Thresholds

Proportion of Patients Achieving Pre-Specified UP/C Thresholds, %



Business Strategy

- Strengthen FILSPARI's position as foundational care in IgAN through continued uptake and new data.
- Prepare for a successful launch in FSGS (if approved) by leveraging IgAN commercial success.
- Successful enrollment in Phase 3 HARMONY Study to position pegtibatinase as the first potential disease-modifying therapy for HCU.
- Strong balance sheet to execute on key strategic priorities.
- Continued investment in strategic rare nephrology and metabolic disease opportunities.

Pipeline of Potential First-in-Class Programs Targeting Rare Kidney and Metabolic Diseases

Program	Therapeutic area	Preclinical	Phase 1	Phase 2	Phase 3	Approved	Commercial
FILSPARI® (sparsentan)[1]	IgAN					✓	FILSPARI® (sparsentan)
Sparsentan[2]	FSGS						
Pegtibatinase (TVT-058)[3]	HCU						
Thiola EC® and Thiola® (tiopronin)	Cystinuria					✓	Thiola EC® (tiopronin) Thiola® (tiopronin)

Abbreviations: IgAN: IgA nephropathy; FSGS: focal segmental glomerulosclerosis; HCU: classical homocystinuria. [1] In September 2024, the FDA granted full approval of FILSPARI (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk for disease progression. [2] In January 2026, Travere announced that the FDA has extended the review period of its sNDA for traditional approval of FILSPARI (sparsentan) for the treatment of FSGS and assigned a new Prescription Drug User Fee Act (PDUFA) target action date of April 13, 2026. [3] In 1Q26, Travere resumed enrollment activities for the pivotal Phase 3 HARMONY Study.

Travere Therapeutics, Inc. | 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130 | ir.travere.com | email: ir@travere.com